AQR Capital Management LLC Buys 14,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• AQR Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 1.8%, holding a total of 828,344 shares worth approximately $217 million.
• Institutional investors now own 92.97% of Alnylam Pharmaceuticals, reflecting significant investor confidence in the company.
• Alnylam Pharmaceuticals reported $0.32 earnings per share for the last quarter, exceeding analysts' expectations and marking a revenue increase of 17.3% year-over-year.

AQR Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 828,344 shares of the biopharmaceutical company's stock after acquiring an additional 14,988 shares during the quarter. AQR Capital Management LLC owned about 0.64% of Alnylam Pharmaceuticals worth $217,026,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $275,000. GAMMA Investing LLC raised its holdings in shares of Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after purchasing an additional 77 shares during the last quarter. Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $243,000. Finally, Silvercrest Asset Management Group LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $1,151,000. Institutional investors own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the sale, the executive vice president directly owned 20,221 shares in the company, valued at $9,269,508.61. The trade was a 6.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,274 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the sale, the executive vice president owned 50,121 shares in the company, valued at $22,718,345.67. The trade was a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,594 shares of company stock worth $25,551,456. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Up 1.5%

NASDAQ:ALNY traded up $6.80 during trading hours on Monday, hitting $458.80. 337,359 shares of the company traded hands, compared to its average volume of 954,839. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The firm's 50-day simple moving average is $387.47 and its 200-day simple moving average is $310.11. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $469.81. The company has a market cap of $60.14 billion, a PE ratio of -185.40 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business's revenue was up 17.3% on a year-over-year basis. During the same period last year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Needham & Company LLC upped their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Jefferies Financial Group increased their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Bank of America raised their price objective on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a report on Friday, July 11th. Finally, UBS Group increased their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $417.38.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.